Identification of the minimal active sequence of an anti-influenza virus peptide

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1810-1813

  Jones, Jeremy C ^a   Settles, Erik W ^b   Brandt, Curtis R ^b,c   Schultz Cherry, Stacey ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE LIBRARY; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IC 50; IN VITRO STUDY; INFLUENZA VIRUS; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; HUMANS; INHIBITORY CONCENTRATION 50; MICROSCOPY, ELECTRON; ORTHOMYXOVIRIDAE; PEPTIDES;

EID: 79953181985     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01428-10     Document Type: Article

References (24)

1. Altmann, S. E., J. C. Jones, S. Schultz-Cherry, and C. R. Brandt. 2009. Inhibition of vaccinia virus entry by a broad spectrum antiviral peptide. Virology 388:248-259.
2. Belshe, R. B., M. H. Smith, C. B. Hall, R. Betts, and A. J. Hay. 1988. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62:1508-1512.
3. Bright, R. A., et al. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175-1181. (Pubitemid 41393595)
4. Bultmann, H., J. S. Busse, and C. R. Brandt. 2001. Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1. J. Virol. 75:2634-2645.
5. Bultmann, H., G. Girdaukas, G. S. Kwon, and C. R. Brandt. 2010. The virucidal EB peptide protects host cells from herpes simplex virus type 1 infection in the presence of serum albumin and aggregates proteins in a detergent-like manner. Antimicrob. Agents Chemother. 54:4275-4289.
6. Centers for Disease Control and Prevention. 2010. Influenza antiviral medications: summary for clinicians. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/flu/professionals/antivirals/summary- clinicians.htm.
7. Cox, R. J., K. A. Brokstad, and P. Ogra. 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59:1-15.
8. De Clercq, E. 2006. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5:1015-1025.
9. de Jong, M. D., et al. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353:2667-2672.
10. Deyde, V. M., et al. 2007. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196:249-257.
11. Fiore, A. E., et al. 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommend. Rep. 59:1-62.
12. Herlocher, M. L., et al. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630.
13. Hirst, G. K. 1942. Adsorption of influenza hemagglutinins and virus by red blood cells. J. Exp. Med. 76:195-209.
14. Hirst, G. K. 1942. The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J. Exp. Med. 75:49-64.
15. Jones, J. C., E. A. Turpin, H. Bultmann, C. R. Brandt, and S. Schultz-Cherry. 2006. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol. 80:11960-11967. (Pubitemid 44904345)
16. Meltzer, M. I., N. J. Cox, and K. Fukuda. 1999. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg. Infect. Dis. 5:659-671.
17. Moscona, A. 2004. Oseltamivir-resistant influenza? Lancet 364:733-734.
18. Nicholson, K. G., J. M. Wood, and M. Zambon. 2003. Influenza. Lancet 362:1733-1745. (Pubitemid 37468326)
19. Stephenson, I., and K. G. Nicholson. 2001. Influenza: vaccination and treatment. Eur. Respir. J. 17:1282-1293.
20. Stiver, G. 2003. The treatment of influenza with antiviral drugs. CMAJ 168:49-56.
21. Thompson, W. W., et al. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340. (Pubitemid 39223224)
22. Thompson, W. W., et al. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-186. (Pubitemid 36068705)
23. Wang, C., K. Takeuchi, L. H. Pinto, and R. A. Lamb. 1993. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J. Virol. 67:5585-5594.
24. Yen, H. L., et al. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49:4075-4084.